Back to Search
Start Over
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
- Source :
-
Cancer investigation [Cancer Invest] 2008 Jun; Vol. 26 (5), pp. 491-8. - Publication Year :
- 2008
-
Abstract
- Randomized phase III trials have demonstrated that the addition of paclitaxel is effective in the adjuvant treatment of breast cancer. Forty-five patients with high-risk resected breast cancer entered this study. They were treated with three cycles of epirubicin every 2 weeks, followed by three cycles of intensified CMF, every 2 weeks, followed 3 weeks later by nine weekly cycles of paclitaxel (E-CMF-T). Forty patients (89%) received all cycles of chemotherapy and dose intensity was sufficiently maintained for all drugs. Toxicity was generally mild to moderate. Two cases of febrile neutropenia were reported. The E-CMF-T regimen is feasible and well tolerated.
- Subjects :
- Adult
Aged
Antineoplastic Combined Chemotherapy Protocols adverse effects
Breast Neoplasms radiotherapy
Breast Neoplasms surgery
Chemotherapy, Adjuvant
Cyclophosphamide administration & dosage
Drug Administration Schedule
Epirubicin administration & dosage
Feasibility Studies
Female
Fluorouracil administration & dosage
Greece
Humans
Methotrexate administration & dosage
Middle Aged
Paclitaxel administration & dosage
Radiotherapy, Adjuvant
Risk Assessment
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Breast Neoplasms drug therapy
Mastectomy
Subjects
Details
- Language :
- English
- ISSN :
- 1532-4192
- Volume :
- 26
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Cancer investigation
- Publication Type :
- Academic Journal
- Accession number :
- 18568771
- Full Text :
- https://doi.org/10.1080/07357900701829785